Harvard Bioscience (HBI) Stock Overview
Develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
HBI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Harvard Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$3.02 |
| 52 Week Low | US$0.21 |
| Beta | 1.53 |
| 1 Month Change | -9.42% |
| 3 Month Change | 25.36% |
| 1 Year Change | -87.64% |
| 3 Year Change | -90.39% |
| 5 Year Change | -87.09% |
| Change since IPO | -88.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| HBI | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 2.4% | -4.2% | 0.4% |
| 1Y | -87.6% | -14.8% | 18.3% |
Return vs Industry: HBI underperformed the German Life Sciences industry which returned -13.1% over the past year.
Return vs Market: HBI underperformed the German Market which returned 19.3% over the past year.
Price Volatility
| HBI volatility | |
|---|---|
| HBI Average Weekly Movement | 38.7% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: HBI's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HBI's weekly volatility has increased from 22% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 343 | Jim Green | www.harvardbioscience.com |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.
Harvard Bioscience, Inc. Fundamentals Summary
| HBI fundamental statistics | |
|---|---|
| Market cap | €17.05m |
| Earnings (TTM) | -€49.66m |
| Revenue (TTM) | €78.18m |
Is HBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBI income statement (TTM) | |
|---|---|
| Revenue | US$91.40m |
| Cost of Revenue | US$39.18m |
| Gross Profit | US$52.22m |
| Other Expenses | US$110.27m |
| Earnings | -US$58.05m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 11, 2025
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 57.14% |
| Net Profit Margin | -63.52% |
| Debt/Equity Ratio | 242.4% |
How did HBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/21 14:58 |
| End of Day Share Price | 2025/07/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harvard Bioscience, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Bruce Jackson | Benchmark Company |
| Paul Knight | Janney Montgomery Scott LLC |